导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.85% | 1870/4773 |
| 近一周 | -0.87% | 1929/5467 |
| 近一月 | -6.27% | 3015/5421 |
| 近一季 | -11.26% | 3478/5238 |
| 近半年 | -4.82% | 3013/4931 |
| 近一年 | 5.57% | 1504/4400 |
| 近两年 | 66.48% | 1069/2954 |
| 近三年 | 29.70% | 1082/2253 |
| 成立以来 | 132.70% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.08% 806/4961 |
17.26% 1480/5312 |
- - |
- - |
| 2025 | 28.22% 1501/4813 |
2.32% 1406/3635 |
1.62% 2259/4076 |
21.10% 1851/4524 |
1.83% 1201/4813 |
| 2024 | 2.26% 1978/3463 |
-7.08% 2114/2808 |
-3.71% 1410/3014 |
13.11% 2239/3129 |
1.04% 1129/3463 |
| 2023 | -0.46% 454/2656 |
6.40% 691/2280 |
-1.54% 500/2385 |
-1.93% 603/2515 |
-3.11% 605/2655 |
| 2022 | -18.06% 657/2207 |
-11.91% 555/1919 |
6.13% 766/2016 |
-10.73% 445/2113 |
-1.83% 1743/2208 |
| 2021 | 27.20% 92/1822 |
0.14% 312/1255 |
17.02% 191/1330 |
9.59% 135/1466 |
-0.95% 1288/1822 |
| 2020 | - - |
- - |
- - |
13.98% 303/1164 |
12.83% 426/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 西部利得中证500指数增强(LOF)C VS. 长安沪深300非周期A(740101) |